Antisense cancer therapeutics with alkylating agents

Antisense oligonucleotide agents combined with DNA alkylating agents, guided by biomarkers, effectively suppress TGF-P2 expression to enhance cancer treatment efficacy and reduce toxicity, addressing limitations of conventional therapies.

WO2026085179A1 Publication Date: 2026-04-23GMP BIOTECHNOLOGY LTD +1
0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/051022
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-10-18
Filing Date
2025-10-15
Publication Date
2026-04-23

AI Technical Summary

Technical Problem

Conventional cancer therapies face limitations in efficacy, toxicity, and side effects, with biomarkers failing to accurately guide treatment and diagnosis, necessitating the development of agents and methods that enhance therapeutic outcomes while minimizing adverse effects.

Method used

The use of antisense oligonucleotide agents to suppress TGF-P2 expression, combined with DNA alkylating agents, and guided by biomarkers such as histone deacetylase and genomic DNA methylation levels, to tailor treatments for specific patient profiles, reducing agent doses and enhancing clinical outcomes.

Benefits of technology

This approach increases survival rates and reduces toxicity by selectively targeting TGF-P2 expression, improving therapeutic efficacy and patient outcomes in cancers like glioma, pancreatic, ovarian, and stomach cancer.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention relates to agents, compositions, and methods for use in treating or ameliorating symptoms of cancer. Exemplary synergistic therapies include the use of antisense oligonucleotide agents for suppressing expression of TGF-β2 in combination with alkylating agents or HDAC inhibitors. Patients can be distinguished by reduced histone deacetylases. Additional therapies include the use of antisense oligonucleotide agents for suppressing expression of TGF-β2 for patients who have (a) low genomic methylation and / or (b) high TGF-β2 expression. Diagnostic information and methods are provided with histone deacetylases.
Need to check novelty before this filing date? Find Prior Art